High affinity probes for analysis of human papillomavirus expression

• US 20070111960A1
• Filed: 09/05/2006
• Published: 05/17/2007
• Est. Priority Date: 03/04/2005
• Status: Abandoned Application

• Current Assignee: Advanex Incorporated
• Original Assignee: Advanex Incorporated
• Inventors: Stender, Henrik, Fiandaca, Mark
• Application Number:
  US11/516,409
• Publication Number:
  US 20070111960A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 1/708 for papilloma
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: G01N 2333/025 Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus

Abstract

This invention is directed toward methods kits and compositions pertaining to the use of high affinity probes for diagnostic applications. The invention is further directed toward the use of the high affinity probes for the detection of clinically important human papillomavirus (HPV) strains. High affinity probes enable rapid diagnostic assays and supply sufficient hybridization specificity to discriminate closely related HPV strains. Examples of high-affinity probes are provided which are specifically directed towards the detection of the E6 and E7 regions, and splice variants thereof of HPV mRNA.

Claims

1. A high affinity probe for expression analysis of an mRNA, comprising a nucleobase sequence complementary to a target sequence of an mRNA.

5. The high affinity probe of claim 1, wherein the high affinity probe is directly detectable.

6. The high affinity probe of claim 1, wherein the probe sequence is between about 8 to about 20 subunits in length.

7. The high affinity probe of claim 1, wherein the probe is labeled with at least one detectable moiety.

8. The high affinity probe of claim 1, wherein the detectable moiety is one ore more of a conjugate, a branched detection system, a chromophore, a fluorophore, a spin label, a radioisotope, an enzyme, a hapten, an acridinium ester, or a luminescent compound.

9. The high affinity probe of claim 1, wherein the probe is self-reporting.

10. The high affinity probe of claim 1, wherein the probe is a PNA Linear Beacon.

11. The high affinity probe of claim 1, wherein the probe further comprises a spacer or a linker.

12. The high affinity probe of claim 1, wherein in situ hybridization is used for analysis of the target sequence.

23. A high affinity probe set, comprising two or more high affinity probes identified in claim 1, wherein the probes are used for the analysis of mRNA expression.

24. The high affinity probe set of claim 23, wherein the probes are used for the analysis of human papillomavirus in a sample.

25. The high affinity probe set of claim 23, wherein the high affinity probes are differently labeled for independent analysis.

26. The high affinity probe set of claim 23, wherein the high affinity probes are directly detectable.

27. A method for expression analysis of mRNA, comprising contacting a cytological specimen with a high affinity probe of claim 1 under conditions suitable for in situ hybridization.

28. A method for expression analysis of a cancer marker, comprising contacting a cytological specimen with a high affinity probe of claim 1 under conditions suitable for in situ hybridization.

29. The method of claim 28, wherein the cancer marker is one or more of Brn-3a, Bcl-2, Her2-neu, p53, E6/E7, E1/E2 or a growth factor receptor.

30. A method for expression analysis of human papillomavirus in a sample comprising:

(a) contacting a cytological specimen with a high affinity probe of claim 1,

(b) incubating the sample with the high affinity probe; and

(c) detecting fluorescence from the sample, wherein the level of fluorescence is indicative of the expression of the human papillomavirus within the sample.

31. The method of claim 30, wherein the in situ hybridization is fluorescence in situ hybridization.

32. The method of claim 27, wherein the probes are directly detectable.

33. The method of claim 27, wherein two or more high affinity probes are used.

34. The method of claim 27, wherein the probes are similarly labeled.

35. The method of claim 27, wherein the probes are differently labeled.

36. The method of claim 27, wherein the detectable moiety is a hapten, wherein the hapten is detected by an enzyme-antibody conjugate capable of producing signal amplification.

37. The method of claim 35, wherein the enzyme in the enzyme-conjugate is selected from a group consisting of alkaline phosphatase, horseradish peroxidase, and soybean peroxidase.

38. The method of claim 35, where the signal amplification is by tyramide signal amplification.

39. The method of claim 30, wherein the probes are a mixture of type-specific HPV probes.

40. The method of claim 30, wherein the stage of HPV-based disease is assessed.

41. The method of claim 30, further comprising a second assay of HPV-based disease.

42. The method of claim 40, wherein the second assay is histological staining.

43. The method of claim 42, wherein the histological staining is Pap staining.

44. The method of claim 40, wherein the second assay is performed on the same cytological specimen.

45. The method of claim 40, wherein the second assay is performed simultaneously with the contacting a cytological specimen with a high affinity probe.

46. The method of claim 40, wherein the second assay is performed prior the contacting a cytological specimen with a high affinity probe.

48. The method of claim 45, wherein the one or more probes are SEQ ID NOS:

1-14 or derivatives thereof.

49. The method of claim 45, wherein the one or more probes are differentially labeled.

50. The method of claim 45, wherein the probes are similarly labeled.

51. The method of claim 45, wherein the determining the presence of bound probe is by in situ hybridization.

52. The method of claim 45, further comprising removing any unbound probe prior to determining the presence of bound probe.

53. The method of claim 45, further comprising correlating the presence or absence of papillomavirus mRNA with a risk of developing HPV-based disease.

54. The method of claim 53, wherein the correlating distinguished between level of risk.

55. The method of claim 54, wherein levels of risk comprise no risk, moderate risk, and high risk.

56. The method of claim 55, wherein no risk correlates with no detectable HPV.

57. The method of claim 55, wherein moderate risk correlates with detection an HPV infection but no detectable HPV-based disease.

58. The method of claim 55, wherein high risk correlates with the detection of high levels of HPV infection.

2. A high affinity probe for expression analysis of a cancer marker, comprising a nucleobase sequence complementary to a target sequence of the cancer marker.

3. The high affinity probe of claim 2, wherein the cancer marker is one or more of Brn-3a, Bcl-2, Her2-neu, p53, E6/E7, E1/E2 or a growth factor receptor.

4. A high affinity probe for expression analysis of human papillomavirus, comprising a nucleobase sequence complementary to a target sequence of human papillomavirus mRNA.

13. The high affinity probe of claim 4, wherein the target sequence is one or more of human papillomavirus E6 or E7 mRNA.

14. The high affinity probe of claim 4, wherein the target sequence is one or more of spliced human papillomavirus E6 or E7 mRNA.

15. The high affinity probe of claim 4, wherein human papillomavirus mRNA is human papillomavirus type 16.

16. The high affinity probe of claim 4, wherein human papillomavirus mRNA is human papillomavirus type 18.

17. The high affinity probe of claim 4, wherein human papillomavirus mRNA is human papillomavirus type 31.

18. The high affinity probe of claim 4, wherein human papillomavirus mRNA is human papillomavirus type 33.

19. The high affinity probe of claim 4, wherein human papillomavirus mRNA is human papillomavirus type 45.

20. The high affinity probe of claim 4, wherein the high affinity probe is a peptide nucleic acid (PNA) probe.

21. The high affinity probe of claim 4, wherein the high affinity probe is a locked nucleic acid (LNA) probe.

22. The high affinity probe of claim 4, wherein the probe comprises one or more of the following sequences:

(HPV16 E6*);

ATA TAG CTC ACG TCG (SEQ ID NO;

     1);

(HPV18 E6*);

AGG CAC CTC TGT MG (SEQ ID NO;

     2);

(HPV31 E6*);

ATA CAC CTC TGT TTC (SEQ ID NO;

     3);

(HPV33 E6*);

ATA CAC CTC AGA TCG (SEQ ID NO;

     4);

(HPV35 E6*);

ATA CAC CTC ACT CCG (SEQ ID NO;

     5);

(HPV16 E7*);

TCC AAA GTA CGA ATG T (SEQ ID NO;

     8);

(HPV18 E7*);

GTC TTC CM AGT ACG A (SEQ ID NO;

6;

(HPV31 E7*);

CTT GCA ATA TGC GAA TAT (SEQ ID NO;

     10);

(HPV33 E7*);

GTA TGG TTC GTA GGT (SEQ ID NO;

     9);

(HPV35 E7*);

TTC CM TTT ACG TAT GTC (SEQ ID NO;

7;

(HPV16 E6 B) TCG CAG TM CTG TTG C (SEQ ID NO;

     11);

(HPV16 E6 C) TCA CGT CGC AGT MC (SEQ ID NO;

     12);

(16E6E7 A) TAA TAC ACC TCA CGT (SEQ ID NO;

     13);

or (16E6E7 B) GTT AAT ACA CCT CAC (SEQ ID NO;

     14).

47. A method of assessing the risk of developing HPV-based disease or cancer, comprising:

a) contacting a sample from a subject with one or more high affinity probes complementary to a target sequence of human papillomavirus mRNA, and

b) determining the presence of bound probe.

59. A method for selecting subjects for treatment for HPV-based disease, comprising

a) contacting a sample from a subject with one or more high affinity probes complementary to a target sequence of human papillomavirus mRNA,

b) determining the presence of bound probe, and

c) correlating the presence of papillomavirus mRNA with a need for treatment for HPV-based diseases.

60. The method of claim 59, further comprising obtaining a sample from the subject.

61. The method of claim 59, further comprising treating a subject for HPV-based diseases based on the presence of papillomavirus mRNA.

62. A method for monitoring the efficacy of an HPV-treatment, comprising

a) determining a pre-treatment level of HPV infection,

b) administering an HPV infection treatment, and

c) determining a post-treatment level of HPV infection after an initial period of treatment.

63. The method of claim 62, further comprising correlating a decrease in the level of infection with an efficacy of treatment.

64. The method of claim 62, wherein the pre-treatment and post-treatment levels of HPV infection are determined by contacting a sample from a subject with one or more high affinity probes complementary to a target sequence of human papillomavirus mRNA and detecting the presence of bound probe.

65. A method for the expression analysis of human papillomavirus by in situ hybridization, comprising:

a) contacting the sample with at least one high-affinity probe that is substantially complementary to a portion of a HPV mRNA.

b) incubating the sample with the high affinity probe; and

c) detecting the fluorescence of the sample, wherein the level of fluorescence is indicative of the presence and/or amount of mRNA within individual cell of the sample.

66. The method of claim 65, wherein the presence of the HPV is by the detection of the expressed mRNA.

67. The method of claim 65, further comprising correlating a level of fluorescence with a down-regulation of expression of HPV mRNA.

68. The method of claim 65, further comprising correlating a level of fluorescence with an up-regulation of expression of HPV mRNA.

69. The method of claim 65, further comprising a comparison of expression of two or more mRNAs.

70. A method of diagnosing or predicting an HPV-based disease in a subject, comprising:

a) determining a level of HPV infection by contacting a sample from a subject with one or more high affinity probes complementary to a target sequence of human papillomavirus mRNA, and determining the presence of bound probe;

b) comparing the level, to a standard level; and

c) correlating a modulated level in the cell from the subject with an indication of an HPV-based disease.

71. The method of claim 70, wherein the standard level is the corresponding level in a reference cell or population of cells.

72. The method of claim 71, wherein the reference cell is one or more of the following, cells from the subject, cultured cells, cultured cells from the subject, cells from the subject pre-treatment, cells from a second subject not suspected or showing no signs of an HPV-based disease.

73. The method of claim 70, further comprising obtaining a cell sample from the subject.

74. The method of claim 70, further comprising reporting the level or correlations thereof to the subject or a health care professional.

75. A kit for expression analysis of human papillomavirus comprising one or more high affinity probes and instructions for use in an in-situ hybridization assay.

76. The kit of claim 75, wherein the kit is used to examine cervical specimens.

77. The kit of claim 76, wherein the cervical specimens are ThinPreps.

78. The kit of claim 76, wherein the cervical specimens have been Pap stained

79. A kit for the assessing the stage of HPV-based diseases, comprising one or more high affinity probes for expression analysis of human papillomavirus, wherein the proved comprises a nucleobase sequence complementary to a target sequence of human papillomavirus mRNA.

80. The kit of claim 79, wherein the high affinity probes are selected from one or more of the probes identified by SEQ ID NOS:

1-14.